Stanford’s 20-year blood-cancer therapy treats first commercial patient; trial found 78% free of GVHD

Stanford's Orca-T therapy, 20 years in development, has received FDA approval and treated its first commercial patient with promising results.

The therapy significantly reduces the risk of graft-versus-host disease post-stem cell transplants.